Short Term Androgen Therapy Might Be Better For More Aggressive Gleason Grade Prostate Cancer

In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]

Tissue Study Could Reshape Advanced Prostate Cancer Treatment & Bio-Markers

A comprehensive study of prostate cancer tissue done in the UK has revealed that a completely new gene network takes over driving the cancer in men who are castrate resistant. The research was published in Cancer Cell. Researchers at the Cancer Research UK Cambridge Research Institute, at the University of Cambridge studied tissue samples from [...]

The Debate Continues, Is IAD or CAD Superior for the Treatment of Men with Castrate Resistant Prostate Cancer?

A new randomized study (FinnProstate Study VII) on the merits of intermittent androgen deprivation (IAD) compared to continuous androgen therapy (CAD) contradicts the recent revelations from the last ASCO presentation (Hussain where the clear conclusion was that CAD was superior to IAD. At the ASCO conference Dr. Hussain’s study concluded that IAD was significantly [...]

Towards An Understanding of the Role of Genetics in Determining Future Treatment Options in Advanced Prostate Cancer – SLCO2B1 and SLCO1B3

We have heard for a period of time that the future of cancer treatment is in genetics. Despite the hubbub, we see very little hard evidence of this in today’s current treatment decisions. Treatment still remains tied into protocols with a strong bias to following a common map. Each map does have little variances, but [...]

ADT2 Shows Survival Advantage Over ADT 1

Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]

Does Androgen-Deprivation Therapy Provide a Survival Benefit? A Look at Survival Outcomes in Men Receiving ADT as Primary or Salvage Treatment for Localized or Advanced Prostate Cancer- Conclusions from a 20-Year Single-Center Experience

The Department of Urology, University of Tennessee Health Science Center, Memphis, TN, performed a retrospective study designed to evaluate the overall survival (OS) and disease-specific survival (DSS) in men receiving primary androgen-deprivation therapy (PADT) or salvage medical ADT (SADT) for prostate cancer. The study included men who were diagnosed and treated with ADT between July [...]

Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer – Which Is Better?

An informative and comprehensive analysis of existing research studies evaluating the merits of early vs. deferred commencement of hormone therapy in men with advanced prostate cancer was recently published. The analysis (Wilt T, Nair B, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database of Systematic [...]

Shorter Adjuvant Androgen-Deprivation Therapy for Prostate Cancer Leads to Reduced Survival

At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]